

**REDX PHARMA LIMITED**

**("Redx" or the "Company")**

**Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress**

**Alderley Park, UK, 14 June 2024** [Redx Pharma](#) (JPJ:REDX), the clinical-stage, small molecule biotechnology company, announces that preclinical data from the Company's oral GI-targeted pan-ROCK inhibitor, RXC008, will be presented in an oral presentation at the Extracellular Matrix Pharmacology Congress ("ECM"), being held in Copenhagen, Denmark, 17-19th June 2024.

RXC008 is a potential first-in-class treatment for fibrostenotic Crohn's disease and is specifically designed to target fibrosis in the gastrointestinal tract and to degrade quickly, if absorbed into the bloodstream, through enzyme-mediated metabolism. Preclinical data from RXC008 has shown strong anti-fibrotic therapeutic effects in multiple animal models of inflammatory bowel disease.

A Phase 1 Healthy Volunteers study of RXC008 (RXC008-0001) commenced in early 2024, with data expected by the year end.

Dr Kirsty Houslay, Principal Scientist at Redx, will make an oral presentation discussing preclinical data from studies of RXC008 in various animal models of fibrosis and Crohn's disease.

Details of the presentation are as follows:

**Title: RXC008, a highly potent GI-targeted pan-ROCK inhibitor, is a first-in-class approach to treat Fibrostenotic Crohn's Disease**

**Plenary Session: Tissue Destruction in Inflammatory Diseases**

**Day/Date: Tuesday 18 June 2024**

**Time: 13:45-15:30 CEST**

**Location: Congress Hall, Tivoli Congress Center**

Following the oral presentation, a copy of the presentation deck will be made available on the Company website at: <https://www.redxpharma.com/scientific-publications/>

## About Crohn's Disease

Crohn's disease affects 1.7m<sup>1</sup> people globally and >70,000 new cases are diagnosed each year. More than 50% of patients<sup>2</sup> with Crohn's disease can develop significant fibrosis and stricture formation within ten years after diagnosis; this fibrosis associated with Crohn's disease is known as fibrostenotic Crohn's disease. The current management of fibrotic strictures of the gastrointestinal tract is primarily surgical as no drugs are specifically approved for fibrosis, which can progress despite intervention with anti-inflammatory therapies.

### **For further information, please contact:**

#### **Redx Pharma Limited**

T: +44 (0)1625 469 918

#### **UK Headquarters**

Caitlin Pearson, Head of Communications

[ir@redxpharma.com](mailto:ir@redxpharma.com)

#### **FTI Consulting**

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

### **About Redx Pharma Limited**

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohns disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated

---

<sup>1</sup> Clarivate, Crohn's disease landscape & forecast pg 39, Published Sep 2022

<sup>2</sup> Chan et al, 2018

targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.